Cannabis extract shows promise for rare genetic disorder in new trial
NCT ID NCT07257978
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tests a cannabis plant extract with very low THC (NTI164) in 40 females aged 4-25 with Rett syndrome, a rare genetic condition causing severe physical and mental challenges. Participants will receive either NTI164 or a placebo, then switch after a period. The goal is to see if NTI164 safely reduces core symptoms like anxiety, communication problems, and movement issues, building on earlier positive results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETT SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Monash Health
Clayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.